Home » Stocks » AMRS

Amyris, Inc. (AMRS)

Stock Price: $2.66 USD 0.24 (9.71%)
Updated November 24, 1:19 PM EST - Market open

Stock Price Chart

Key Info

Market Cap 635.11M
Revenue (ttm) 133.93M
Net Income (ttm) -352.02M
Shares Out 239.21M
EPS (ttm) -2.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 24
Last Price $2.66
Previous Close $2.42
Change ($) 0.24
Change (%) 9.71%
Day's Open 2.51
Day's Range 2.46 - 2.70
Day's Volume 1,796,839
52-Week Range 1.40 - 6.07

More Stats

Market Cap 635.11M
Enterprise Value 792.12M
Earnings Date (est) Mar 3, 2021
Ex-Dividend Date n/a
Shares Outstanding 239.21M
Float 134.53M
EPS (basic) -2.05
EPS (diluted) -2.04
FCF / Share -0.98
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 24.72M
Short Ratio 15.41
Short % of Float 18.37%
Beta 0.73
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 4.74
PB Ratio n/a
Revenue 133.93M
Operating Income -152.32M
Net Income -352.02M
Free Cash Flow -222.97M
Net Cash -157.01M
Net Cash / Share -0.66
Gross Margin 8.89%
Operating Margin -113.73%
Profit Margin -262.80%
FCF Margin -166.48%
ROA -56.92%
ROE n/a
ROIC -96.50%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$8.50*
(220.15% upside)
Low
6.00
Current: $2.66
High
11.00
Target: 8.50
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue15363.6012867.1934.1543.2741.1273.6914780.31
Revenue Growth139.85%-50.18%90.01%96.74%-21.08%5.24%-44.2%-49.86%83.03%-
Gross Profit76.3726.9165.3610.51-3.2210.072.87-3.62-8.629.80
Operating Income-122-137-56.05-95.92-149-99.83-120-202-179-83.79
Net Income-243-230-156-97.33-2182.29-235-205-179-81.87
Shares Outstanding10160.4132.2515.908.465.235.033.782.990.99
Earnings Per Share-2.72-3.69-6.26-6.55-26.20-13.50-46.80-54.30-59.85-125.24
Operating Cash Flow-157-109-101-82.37-85.13-84.71-106-151-92.50-64.58
Capital Expenditures-13.08-12.47-4.41-0.92-3.37-5.00-8.09-56.86-97.02-15.51
Free Cash Flow-170-122-106-83.29-88.50-89.71-114-208-190-80.09
Cash & Equivalents0.7446.0960.0532.8514.6945.049.9431.64104258
Total Debt94.2421016422715323315310747.6612.59
Net Cash / Debt-93.50-164-104-194-138-188-143-75.1355.93245
Assets161128141130106216199243320357
Liabilities41134035330826534133517715949.91
Book Value-256-218-218-184-158-124-13567.11161308
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Amyris, Inc.
Country United States
Employees 561
CEO John G. Melo

Stock Information

Ticker Symbol AMRS
Stock Exchange NASDAQ
Sector Basic Materials
Industry Specialty Chemicals
Unique Identifier NASDAQ: AMRS
IPO Date September 28, 2010

Description

Amyris, a biotechnology company, develops technology that creates microbial strains to produce artemisinic acid, a precursor of artemisinin, an anti-malarial drug. The company's technology platform enables to engineer microbes and use them as catalysts to metabolize renewable, plant-sourced sugars into large volume, high-value ingredients. It applies technology platform to engineer, manufacture, and sell products for the clean health and beauty, and flavor and fragrance markets. The company operates under the Amyris, Biofene, Biossance, Pipette, Purecane, and No Compromise trademarks. Amyris, Inc. has a collaboration agreement with the Infectious Disease Research Institute to advance a novel ribonucleic acid vaccine platform, including accelerating the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.